This week in Psychiatry

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Psychiatry. This week we're covering 10 notable papers spanning new approaches to depression and acute trauma, the long arc of schizophrenia treatment, and a set of sobering negative and reframing findings in suicide prevention, addiction and neurodevelopment. Let's dive in.

We start with acute and preventive interventions, where two short-acting nasal treatments and one wartime care model all aim to deliver more in less time. In JAMA, Feifel and colleagues report a phase 2b double-blind trial of a single intranasal dose of mebufotenin, also known as 5-MeO-DMT, in 193 adults with treatment-resistant depression across 38 sites in Australia, Europe and the United States [1]. Participants received 8 milligrams, 12 milligrams, or a 0.3 milligram low-dose comparator alongside psychological support. At day 29, the 12 milligram dose lowered depression scores by about five more points on the Montgomery-Åsberg scale than the comparator, and the 8 milligram dose performed similarly, with separation holding from day 2 through day 57. Response rates were roughly a third in both active arms against about one in eight on the low dose. Most adverse events were mild or moderate, and roughly four in five participants were ready for discharge within two hours, which the authors contrast with the much longer monitoring that psilocybin requires. This is one phase 2b trial with an active low-dose comparator, and blinding with a psychedelic is always imperfect, so phase 3 data are still needed before this changes care. In JAMA Internal Medicine, Huang and colleagues tested something quite different: a single 40 unit dose of intranasal oxytocin given ten minutes before anaesthesia in 328 adults undergoing traumatic fracture surgery in a single Chinese centre [2]. Screening-positive probable acute stress disorder within three days fell from about 30 percent on saline to about 16 percent on oxytocin, roughly halving the risk, with no serious adverse events. The outcome was a questionnaire screen rather than a clinical diagnosis, follow-up was short, and it is a single-site trial, so whether this prevents later post-traumatic stress disorder remains unknown. On the systems side, JAMA Psychiatry carries a Special Communication from Berezyuk and colleagues describing the Unbroken model in a civilian hospital in Lviv during the war in Ukraine [3]. Through proactive psychiatric rounds across surgical wards, triage into four pathways and stabilisation-first sequencing, more than 7,500 people received psychiatric care, over 4,000 of them trauma-focused psychotherapy. It is a descriptive implementation report without outcome comparisons, but it offers a practical template for integrating trauma care into medical settings at scale.

Our second theme is schizophrenia, from population-level medication effects down to augmentation and cognitive rehabilitation. In Molecular Psychiatry, Yao and colleagues pooled 68 observational studies covering more than 1.4 million people with schizophrenia [4]. Antipsychotic use was associated with roughly a third lower all-cause mortality and substantially lower relapse risk than nonuse, but also with about 40 percent higher cancer risk, about a third higher fracture risk, and about a quarter higher risk of lung infections. The authors are explicit that residual confounding precludes causal claims and that several estimates rest on few studies; still, the picture supports continued treatment while sharpening attention to bone health, infection and cancer screening. For patients who fail clozapine, Baldwin and colleagues in Schizophrenia Bulletin reviewed 88 tertiary admissions in British Columbia [5]. Amisulpride-type selective antagonist augmentation was associated with discharge happening about two and a half times faster than with electroconvulsive therapy, while aripiprazole-type partial agonism showed no such advantage and had the most switching for inefficacy. Electroconvulsive therapy, however, produced greater reductions in positive symptoms, and was chosen more often for patients who were more impaired on admission, which confounds the comparison. This is a small retrospective cohort, so it frames a trade-off between efficiency and symptom response rather than settling sequencing. Also in Schizophrenia Bulletin, Medalia and colleagues tested whether personalising cognitive remediation by adding early auditory processing training helps patients with auditory deficits [6]. Among 184 outpatients, adding auditory training made no significant difference to cognitive or functional outcomes in either group, although cognitive remediation overall produced moderate gains and auditory deficits improved modestly regardless of arm. The primary personalisation hypothesis was not supported; the value of standard cognitive remediation was.

Our third theme concerns suicide prevention and addiction, where the question is less whether to intervene than which kind of follow-up fits which patient. In the American Journal of Psychiatry, Radin and colleagues report the SPARC pragmatic trial of more than 1,500 adolescents and adults who screened at risk for suicide in emergency departments and primary care [7]. Participants were randomised to instrumental support calls or two-way Caring Contacts text messages. In adults, suicidal ideation and behaviour scores were higher at six months with texts than with calls, with no difference by twelve months. In adolescents, the pattern reversed over time: no difference at six months, but lower scores with texts at twelve months. The samples were predominantly White and female, and both arms received usual care plus an active intervention, so this compares two reasonable options rather than testing either against nothing. The authors conclude that the best follow-up may differ by age, with adults gaining more from intensive early practical support and adolescents from longer-term connection. In JAMA Psychiatry, Huang and colleagues randomised inpatients with opioid use disorder to Mindfulness-Oriented Recovery Enhancement or supportive psychoeducation [8]. The mindfulness programme shifted prefrontal responses away from drug cues and toward natural rewards, a shift linked to lower craving, and extended abstinence at roughly four months after treatment. With only 59 participants in the imaging analysis and smaller follow-up subsets, the clinical signal is modest and early, but it adds mechanistic plausibility to mindfulness as an adjunct to medication.

Our final theme is neurodevelopment, where two papers temper popular assumptions. In the American Journal of Psychiatry, Eraydin and colleagues report secondary outcomes from a multicentre sham-controlled trial of external trigeminal nerve stimulation in 150 young people with attention deficit hyperactivity disorder [9]. Four weeks of nightly stimulation produced no significant effect on any cognitive, autonomic or head motion measure, at the end of treatment or at six months. Coming after the same group's negative clinical findings, this is a fairly firm negative result for a device that holds Food and Drug Administration clearance. And in Biological Psychiatry, Kim and colleagues systematically reviewed 27 autism incidence studies [10]. Rising incidence appeared mainly in administratively defined populations with moderate or low case ascertainment and in broader diagnostic categories, while the most comprehensive birth cohorts showed inconsistent trends. The authors conclude the data do not provide compelling evidence of a true autism epidemic, pointing instead to diagnostic and ascertainment changes, though heterogeneity prevented formal pooling.

If you only have time for one paper this week, make it the mebufotenin trial in JAMA [1]. It reopens the question of whether psychedelic-assisted treatment for resistant depression can be delivered within a two-hour visit, which goes directly to the access problem that has limited psilocybin.

Here is what this week's evidence adds up to in Psychiatry. First, a single short-acting intranasal psychedelic showed rapid and durable antidepressant effects in treatment-resistant depression, but this is phase 2b evidence awaiting phase 3 confirmation. Second, preoperative oxytocin roughly halved screen-positive acute stress after fracture surgery in one single-centre trial, with long-term and diagnostic outcomes still unknown. Third, observational data continue to associate antipsychotics with lower mortality and relapse alongside higher fracture, infection and cancer risk, and causality remains unproven. Fourth, the right post-crisis suicide follow-up may depend on age, according to a large pragmatic trial whose population was not very diverse. Fifth, several hoped-for interventions were negative this week, including trigeminal nerve stimulation for cognition in attention deficit hyperactivity disorder and personalised auditory training in schizophrenia, while the autism incidence review argues the apparent epidemic largely reflects ascertainment.

That's your roundup for This Week in Psychiatry. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.